Wall Street analysts predict that Icon Plc (NASDAQ:ICLR) will report earnings of $1.60 per share for the current quarter, according to Zacks. Seven analysts have made estimates for Icon’s earnings. The highest EPS estimate is $1.62 and the lowest is $1.57. Icon posted earnings per share of $1.43 in the same quarter last year, which indicates a positive year-over-year growth rate of 11.9%. The company is scheduled to issue its next quarterly earnings report on Thursday, February 21st.
On average, analysts expect that Icon will report full-year earnings of $6.08 per share for the current fiscal year, with EPS estimates ranging from $6.05 to $6.11. For the next fiscal year, analysts expect that the company will report earnings of $6.79 per share, with EPS estimates ranging from $6.60 to $6.98. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Icon.
Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 24th. The medical research company reported $1.54 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.54. The business had revenue of $655.02 million during the quarter, compared to the consensus estimate of $654.66 million. Icon had a net margin of 12.88% and a return on equity of 26.08%.
ICLR has been the subject of a number of recent research reports. Robert W. Baird boosted their price target on shares of Icon from $154.00 to $157.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 11th. BidaskClub raised shares of Icon from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 1st. Evercore ISI raised shares of Icon from an “in-line” rating to an “outperform” rating in a research note on Friday, October 26th. Zacks Investment Research downgraded shares of Icon from a “hold” rating to a “sell” rating in a research note on Wednesday, October 24th. Finally, UBS Group initiated coverage on shares of Icon in a research note on Tuesday, October 9th. They set a “sell” rating and a $145.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $148.00.
A number of large investors have recently modified their holdings of ICLR. WCM Investment Management CA increased its stake in Icon by 7.9% in the third quarter. WCM Investment Management CA now owns 5,000,711 shares of the medical research company’s stock valued at $768,860,000 after purchasing an additional 367,131 shares in the last quarter. Clearbridge Investments LLC increased its stake in Icon by 9.8% in the third quarter. Clearbridge Investments LLC now owns 2,211,986 shares of the medical research company’s stock valued at $340,093,000 after purchasing an additional 198,271 shares in the last quarter. Partner Fund Management L.P. increased its stake in Icon by 61.1% in the second quarter. Partner Fund Management L.P. now owns 432,312 shares of the medical research company’s stock valued at $57,294,000 after purchasing an additional 163,959 shares in the last quarter. Advisors Asset Management Inc. increased its stake in Icon by 3,097.7% in the second quarter. Advisors Asset Management Inc. now owns 153,202 shares of the medical research company’s stock valued at $650,000 after purchasing an additional 148,411 shares in the last quarter. Finally, Redwood Investments LLC bought a new stake in Icon in the second quarter valued at approximately $16,964,000. 86.54% of the stock is owned by hedge funds and other institutional investors.
ICLR opened at $139.63 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.76 billion, a P/E ratio of 25.91, a price-to-earnings-growth ratio of 2.06 and a beta of 0.55. Icon has a fifty-two week low of $101.22 and a fifty-two week high of $155.33.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also: What is a Futures Contract?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.